

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 21801

Title: Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

Reviewer's code: 02431866

Reviewer's country: United States

Science editor: Yue-Li Tian

Date sent for review: 2015-07-31 14:45

Date reviewed: 2015-08-22 04:55

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The current study reported prognosis impact of CD1d-restricted natural killer T (iNKT) cells, antibody-dependent cell-mediated cytotoxicity (ADCC) and their correlation with EGFR level, mutational status of KRAS, NRAS, and BRAF in metastatic colorectal cancer (mCRC) patients. Though the sample size (n=41) is limited, which was also indicated by the author, this study provides some interesting information, particularly for cetuximab mediated ADCC. However, the manuscript has to be improved to be more informative to the audience. (1) Please spell out iNKT, ADCC, NK, LDH etc. in the abstract. (2) In the abstract, please briefly state that the "standard techniques" are for the mutation analysis. (3) Figure 2 is currently missing. (4) The discussion section is too long to be balanced with the result section. You may consider deleting some clinical trial information and focusing the discussion on the result. (5) No multivariate statistical analysis was performed for disease free and overall survival analyses.